3,3′-diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: A pilot study

Thyroid

Volumn 21, Issue 3, 2011, Pages 299-304

  Rajoria, Shilpi ^a   Suriano, Robert ^a   Parmar, Perminder Singh ^b   Wilson, Yushan Lisa ^b   Megwalu, Uchechukwu ^b   Moscatello, Augustine ^b   Bradlow, H Leon ^c   Sepkovic, Daniel W ^c   Geliebter, Jan ^a   Schantz, Stimson P ^b   Tiwari, Raj K ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; 3,3' DIINDOLYLMETHANE; BIORESPONSE; ESTROGEN; UNCLASSIFIED DRUG; 3,3'-DIINDOLYLMETHANE; INDOLE DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CRUCIFERA; DIET SUPPLEMENTATION; ESTROGEN METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; MODULATION; PILOT STUDY; PRIORITY JOURNAL; SUBTOTAL THYROIDECTOMY; THYROID DISEASE; THYROID PROLIFERATIVE DISEASE; THYROIDECTOMY; TISSUE SLICE; URINALYSIS; VEGETABLE; CLINICAL TRIAL; METABOLISM; PHASE 1 CLINICAL TRIAL; THYROID GLAND; THYROID TUMOR; URINE;

ESTROGENS; FEMALE; HUMANS; INDOLES; PILOT PROJECTS; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 79952372801     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2010.0245     Document Type: Article

References (28)

1. Lord RS, Bongiovanni B, Bralley JA 2002 Estrogen metabolism and the diet-cancer connection: rationale for assessing the ratio of urinary hydroxylated estrogen metabolites. Altern Med Rev 7:112-129. (Pubitemid 34461523)
2. Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH 1998 Do urinary estrogen metabolites predict breast cancer? Follow up of the Guernsey III cohort. Br J Cancer 78:1250-1255. (Pubitemid 28479160)
3. Schneider J, Huh MM, Bradlow HL, Fishman J 1984 Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 259:4840-4845. (Pubitemid 14144204)
4. Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL 1992 Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 84:634-638.
5. Ho GH, Luo XW, Ji CY, Foo SC, Ng EH 1998 Urinary 2/16alpha-hydroxyestorne ratio: correlation with serum insulinlike growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singap 27:294-299. (Pubitemid 128518764)
6. Zheng W, Dunning L, Jin F, Holtzman J 1997 Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomark Prev 6:505-509.
7. Ursin G, London S, Stanczk FZ, Gentzschein E, Paganini-Hill A, Ross RK, Pike MC 1999 Urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91:1067-1072. (Pubitemid 29293046)
8. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F 2000 Metabolism and risk of breast cancer: a prospective analysis of 2:16 hydroxyestrone ratio and risk of breast cancer in premenopausal and postmenopausal women. Cancer Epidemiol 11:635-640.
9. Pasagian-Macauley A, Meilahan EN, Bradlow HL, Sepkovic DW, Buhari AM, Simkin-Silverman L, Wing RR, Kuller LH 1996 Urinary markers of estrogen metabolism in premenopausal women. Steroids 61:461-467.
10. Telang NT, Katdare M, Bradlow HL, Osborne MP 1997 Estradiol metabolism: an endocrine biomarker for modulation of human mammary carcinogenesis. Environ Health Perspect 105:559-564. (Pubitemid 27246416)
11. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ 2009 Cancer statistics. CA Cancer J Clin 59:225-249.
12. Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J, Tiwari RK 2010 Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid 20:33-41.
13. Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M 1999 Estradiol increases proliferation and down-regulates the sodium/iodide symporter gene in FRTL-5 cells. Endocrinology 140:5705-5711.
14. Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M 2001 Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab 86:1072-1077. (Pubitemid 32322984)
15. Chan EK, Sepkovic DW, Yoo Bowne HJ, Yu GP, Schantz SP 2006 A hormonal association between estrogen metabolism and proliferative thyroid disease. Otolaryngol Head Neck Surg 134:893-900. (Pubitemid 43766554)
16. Ashok BT, Chen YG, Liu X, Garikapaty VP, Seplowitz R, Tschorn J, Roy K, Mittelman A, Tiwari RK 2002 Multiple molecular targets of indole-3-carbinol, a chemopreventive anti-estrogen in breast cancer. Eur J Cancer Prev 2: S86-S93. (Pubitemid 35265867)
17. Bradlow HL, Sepkovic DW 2002 Diet and breast cancer. Ann NY Acad Sci 963:247-267. (Pubitemid 34721718)
18. Sarkar FH, Li Y 2009 Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat Rev 35:597-607.
19. Bode AM, Dong Z 2009 Cancer prevention research-then and now. Nat Rev Cancer 9:508-516.
20. Garikapaty VP, Ashok BT, Chen YG, Mittelman A, Iatropoulos M, Tiwari RK 2005 Anti-carcinogenic and antimetastatic properties of indole-3-carbinol in prostate cancer. Oncol Rep 13:89-93.
21. Tiwari RK, Guo L, Bradlow HL, Telang NT, Osborne MP 1994 Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent. J Natl Cancer Inst 86:126-131.
22. Sepkovic DW, Bradlow HL, Bell M 2002 Quantitative determination of 3, 30-diindolylmethane in the urine of individuals receiving indole-3-carbinol. Nutr Cancer 41:57-63.
23. Li Y, Wang Z, Kong D, Murthy S, Dou QP, Sheng S, Reddy GP, Sarkar FH 2007 Regulation of FOXO3a/β-catenin/GSK-3β signaling by 3, 3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 282:21542-21550. (Pubitemid 47099972)
24. Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, Sakr WA, Raz A 2007 Inactivation of NF-κB by 3, 3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 6:2757-2765. (Pubitemid 350064073)
25. Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF 2004 Pilot study: effect of 3, 30-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer 50:161-167.
26. Lotinun S, Westerlind KC, Turner RT 2001 Tissue-selective effects of continuous release of 2-hydroxyestrone and 16alpha-hydroxyestroneonbone, uterus and mammary gland in ovariectomized growing rats. J Endocrinol 170:165-174. (Pubitemid 32677578)
27. Zeligs MA, Sepkovic DW, Manrique C, Macsalka M, Williams DE, Bradlow HL 2002 Absorption-enhanced 3, 3′diindolylmethane: human use in HPV-relaed, benign and pre-cancerous conditions. Proc Am Assoc Cancer Res 43:3198 (abstract).
28. Krishnaraj R, Morrissey RL, Crowell J, Lyubimov AV 2004 A four-week oral toxicity study of 3, 3′-diindolylmethane in dogs. Proc Am Assoc Cancer Res 45:735 (abstract).